Tralokinumab
ADBRY
What it isIL-13 monoclonal antibody; moderate-to-severe atopic dermatitis.
Why this oneUnlike dupilumab, it isolates IL-13 rather than blocking both IL-4 and IL-13 signaling.
What limits itConjunctivitis and injection-site reactions are the main tolerability problems.
FDA-approved for
- Moderate-to-severe atopic dermatitis (2021)
FDA label
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Moderate-to-severe atopic dermatitis | Adults | Loading 600 mg SC (four 150 mg or two 300 mg), then 300 mg every other week | May consider 300 mg q4w after 16 wk if clear/almost clear and <100 kg | — |
| Moderate-to-severe atopic dermatitis | Pediatric 12–17 y | Loading 300 mg SC (two 150 mg), then 150 mg every other week | 150 mg every other week | — |
Renal Undefined
Hepatic Undefined
Instructions
- SC injection into thigh or abdomen (upper arm if given by caregiver)
- Complete age-appropriate vaccinations before starting
- May be used with or without topical corticosteroids
- Allow to reach room temperature before injecting; do not inject into damaged/bruised skin
- Autoinjector for adults only; prefilled syringe for ≥12 y
Cautions
- Hypersensitivity, including anaphylaxis and angioedema
- Conjunctivitis and keratitis
- Treat pre-existing helminth infections before starting
- Avoid live vaccines during treatment
Adverse reactions
- Upper respiratory tract infections
- Conjunctivitis
- Injection site reactions
- Eosinophilia
Pregnancy Limited human data; monoclonal antibody actively transported across placenta; no adverse effects in animals
Lactation No data; maternal IgG present in breast milk
NO BOXED WARNINGS
Principal riskConjunctivitis, though less than with dupilumab
Classes and tags
Clinical profile
Mechanism of action: Tralokinumab ballicule
Open Tralokinumab in the interactive console ↗
Memory aids: mascots and interaction avatars
